Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Alnylam Pharmaceuticals, Inc. (ALNY : NSDQ)
 
 • Company Description   
Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year..

Number of Employees: 1,665

 
 • Price / Volume Information   
Yesterday's Closing Price: $132.27 Daily Weekly Monthly
20 Day Moving Average: 975,655 shares
Shares Outstanding: 120.81 (millions)
Market Capitalization: $15,980.01 (millions)
Beta: 0.95
52 Week High: $212.00
52 Week Low: $117.58
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -20.80% -13.28%
12 Week -14.66% -4.09%
Year To Date -22.00% -4.71%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
675 WEST KENDALL STREET HENRI A. TERMEER SQUARE
-
CAMBRIDGE,MA 02142
USA
ph: 617-551-8200
fax: 617-551-8101
investors@alnylam.com http://www.alnylam.com
 
 • General Corporate Information   
Officers
Yvonne L. Greenstreet - Chief Executive Officer and Director
Jeffrey V. Poulton - Executive Vice President and Chief Financial Offic
Dennis A. Ausiello - Director
Michael W. Bonney - Director
Olivier Brandicourt - Director

Peer Information
Alnylam Pharmaceuticals, Inc. (CORR.)
Alnylam Pharmaceuticals, Inc. (RSPI)
Alnylam Pharmaceuticals, Inc. (CGXP)
Alnylam Pharmaceuticals, Inc. (BGEN)
Alnylam Pharmaceuticals, Inc. (GTBP)
Alnylam Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 02043Q107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/02/22
Share - Related Items
Shares Outstanding: 120.81
Most Recent Split Date: (:1)
Beta: 0.95
Market Capitalization: $15,980.01 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.58 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-6.78 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/02/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 39.83
Price/Cash Flow: -
Price / Sales: 18.16
EPS Growth
vs. Year Ago Period: -16.96%
vs. Previous Quarter: 7.41%
Sales Growth
vs. Year Ago Period: 20.10%
vs. Previous Quarter: -17.51%
ROE
03/31/22 - -137.44
12/31/21 - -109.21
09/30/21 - -94.37
ROA
03/31/22 - -25.40
12/31/21 - -24.58
09/30/21 - -24.57
Current Ratio
03/31/22 - 4.27
12/31/21 - 4.04
09/30/21 - 4.38
Quick Ratio
03/31/22 - 4.14
12/31/21 - 3.91
09/30/21 - 4.22
Operating Margin
03/31/22 - -101.46
12/31/21 - -101.01
09/30/21 - -111.82
Net Margin
03/31/22 - -101.46
12/31/21 - -101.01
09/30/21 - -111.82
Pre-Tax Margin
03/31/22 - -101.39
12/31/21 - -100.93
09/30/21 - -111.49
Book Value
03/31/22 - 3.32
12/31/21 - 4.92
09/30/21 - 6.32
Inventory Turnover
03/31/22 - 1.67
12/31/21 - 1.64
09/30/21 - 1.51
Debt-to-Equity
03/31/22 - 1.69
12/31/21 - 1.15
09/30/21 - 0.57
Debt-to-Capital
03/31/22 - 62.78
12/31/21 - 53.46
09/30/21 - 36.46
 

Powered by Zacks Investment Research ©